Abacavir Linked to Increased CVD Risk

Assessment of patients on abacavir in the Swiss Cohort Study found a gradual increase in risk over time.

With today's antiretroviral therapy regimens, HIV-infected patients are surviving to older ages, and cardiovascular disease (CVD) is becoming the most common cause of death. Abacavir, a nucleoside reverse-transcriptase inhibitor that, in combination with 3TC and dolutegravir, is recommended by the Department of Health and Human Services as a first-line therapy, has been linked to an increased risk for CVD in some studies.

Now, investigators have assessed the effect of abacavir on risk for CVD events in the Swiss HIV Cohort Study. Using a new structural Cox model, they estimated this effect as a flexible function of past exposure to the drug, adjusting for CVD risk factors (i.e., hypertension, dyslipidemia, diabetes, renal dysfunction, CD4-ce…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Abacavir Linked to Increased CVD Risk

Topics

Reviewing Author